Eikon Therapeutics offers large modeled analyst upside typical of a speculative biotech, but weak quality metrics, margin compression, leverage, and consecutive earnings misses keep the risk profile elevated.
Thesis pillars
- Value Trap Margin Leverage↓Deteriorating
- Quality Below Floor No Moat→Stable
- Overbought Bear Rally Momentum↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Mar 30, 2026
Eikon Therapeutics, Inc. (EIKN) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $5.54, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: in-licensed product candidates; DATA_ISSUE: analyst_target_implausible (raw $24.33 vs price $5.54 — ratio 4.4×). Rejected, falling back to technical TP..
Eikon Therapeutics is a late-stage clinical biopharmaceutical company using its proprietary single molecule tracking (SMT) technology platform to discover and develop cancer therapeutics, led by drug developers Dr. Roger Perlmutter and Dr. Roy Baynes. The company's most advanced... Read more
Hold if already holding. Not a fresh buy at $5.54, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: in-licensed product candidates; DATA_ISSUE: analyst_target_implausible (raw $24.33 vs price $5.54 — ratio 4.4×). Rejected, falling back to technical TP.. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $300M below $400M minimum. Not in investable universe. Score 4.7/10, moderate confidence.
Passes 4/8 gates (clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Eikon Therapeutics, Inc.
Latest news
- NEWS Eikon Therapeutics Presents Updated Clinical Data for EIK1001 at ESMO 2026 — fiscal.ai Oct 26, 2026
- NEWS Eikon Therapeutics Announces EIK1001 Plus Pembrolizumab And Chemotherapy In First-Line, Stage 4 Non-Small Cell Lung Canc — benzinga Oct 26, 2026
- NEWS Eikon Therapeutics Presents Clinical Data for PARP1 and WRN Helicase Programs at ESMO 2026 — fiscal.ai Oct 23, 2026
- NEWS Eikon Therapeutics Presents Initial And Updated Data For EIK1003 And Initial Data For EIK1004 And EIK1005 At ESMO 2026; — benzinga Oct 23, 2026
- NEWS Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the 2026 ESMO Congress — fiscal.ai Oct 19, 2026
Generated 2026-10-29T13:34:02Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyin-licensed product candidates10-K Item 1A: 'EIK1005 is the only product candidate in clinical development that has leveraged our technology platform. Rights related to all other clinical-stage products candidates are in-licensed.'
Material Events(8-K, last 90d)
- 2026-06-10Item 5.02LOWEikon Therapeutics appointed Ma. Fatima D. Francisco to its Board of Directors as a Class I director effective June 15, 2026, to serve on the Compensation Committee; she will receive standard non-employee director compensation including a $50,000 annual retainer and an option to purchase 85,937 shares at $8.96 per share.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 13.0% daily ATR makes tight stops impractical. Position-size conservatively.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $5.54, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: in-licensed product candidates; DATA_ISSUE: analyst_target_implausible (raw $24.33 vs price $5.54 — ratio 4.4×). Rejected, falling back to technical TP.. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $300M below $400M minimum. Not in investable universe. Resistance target $8.31 (+50.0%), stop $5.16 (−7.4%), A.R:R 0.0:1. Score 4.7/10, moderate confidence.
Resistance target: $8.31 (+50.0% upside). Resistance target $8.31 (+50.0%), stop $5.16 (−7.4%), A.R:R 0.0:1. Stop-loss: $5.16.
Concentration risk — Counterparty: in-licensed product candidates; DATA_ISSUE: analyst_target_implausible (raw $24.33 vs price $5.54 — ratio 4.4×). Rejected, falling back to technical TP.; Market cap $300M below $400M minimum.
Eikon Therapeutics, Inc. trades at a P/E of N/A (forward -0.8). TrendMatrix value score: 5.0/10. Verdict: Hold.
12 analysts cover EIKN with a consensus score of 3.9/5. Average price target: $24.
What does Eikon Therapeutics, Inc. do?Eikon Therapeutics is a late-stage clinical biopharmaceutical company using its proprietary single molecule tracking...
Eikon Therapeutics is a late-stage clinical biopharmaceutical company using its proprietary single molecule tracking (SMT) technology platform to discover and develop cancer therapeutics, led by drug developers Dr. Roger Perlmutter and Dr. Roy Baynes. The company's most advanced candidate, EIK1001, a TLR 7/8 dual-agonist in-licensed from Seven and Eight Biotherapeutics, is in a global Phase 2/3 registrational trial combined with pembrolizumab for advanced melanoma, alongside PARP1 inhibitors EIK1003 and EIK1004 and internally discovered candidate EIK1005.